SG131029A1 - New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it - Google Patents

New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it

Info

Publication number
SG131029A1
SG131029A1 SG200605972-9A SG2006059729A SG131029A1 SG 131029 A1 SG131029 A1 SG 131029A1 SG 2006059729 A SG2006059729 A SG 2006059729A SG 131029 A1 SG131029 A1 SG 131029A1
Authority
SG
Singapore
Prior art keywords
agomelatine
pharmaceutical compositions
compositions containing
new association
thymoregulatory
Prior art date
Application number
SG200605972-9A
Other languages
English (en)
Inventor
Christian De Bodinat
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36190792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG131029(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SG131029A1 publication Critical patent/SG131029A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/08—Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG200605972-9A 2005-09-09 2006-08-31 New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it SG131029A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509208A FR2890563B1 (fr) 2005-09-09 2005-09-09 Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
SG131029A1 true SG131029A1 (en) 2007-04-26

Family

ID=36190792

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200605972-9A SG131029A1 (en) 2005-09-09 2006-08-31 New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it

Country Status (38)

Country Link
US (1) US7902180B2 (pl)
EP (2) EP2301527A1 (pl)
JP (1) JP2007077149A (pl)
KR (2) KR20070029607A (pl)
CN (1) CN1927194A (pl)
AP (1) AP3045A (pl)
AR (1) AR055418A1 (pl)
AT (1) ATE519482T1 (pl)
AU (1) AU2006209371B2 (pl)
BR (1) BRPI0603767A (pl)
CA (1) CA2558764C (pl)
CY (1) CY1112223T1 (pl)
DK (1) DK1762238T3 (pl)
EA (1) EA014381B1 (pl)
ES (1) ES2371482T3 (pl)
FR (1) FR2890563B1 (pl)
GE (1) GEP20094741B (pl)
GT (1) GT200600410A (pl)
HR (1) HRP20110749T1 (pl)
JO (1) JO2746B1 (pl)
MA (1) MA28504B1 (pl)
ME (1) ME01964B (pl)
MX (1) MXPA06010234A (pl)
MY (1) MY162318A (pl)
NO (1) NO338079B1 (pl)
NZ (1) NZ549727A (pl)
PE (1) PE20070613A1 (pl)
PL (1) PL1762238T3 (pl)
PT (1) PT1762238E (pl)
RS (1) RS52003B (pl)
SA (1) SA110320045B1 (pl)
SG (1) SG131029A1 (pl)
SI (1) SI1762238T1 (pl)
TW (1) TWI369980B (pl)
UA (1) UA83541C2 (pl)
UY (1) UY29776A1 (pl)
WO (1) WO2007028903A1 (pl)
ZA (1) ZA200607532B (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CZ20013786A3 (cs) * 1999-04-29 2002-02-13 Merck Patent Gmbh Inhibitory glycinového ątěpicího systému jako moľná antipsychotika
EP1600168A3 (en) * 1999-12-01 2009-09-23 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
FR2884714B1 (fr) * 2005-04-20 2011-05-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires

Also Published As

Publication number Publication date
US7902180B2 (en) 2011-03-08
PE20070613A1 (es) 2007-07-30
MA28504B1 (fr) 2007-04-03
FR2890563B1 (fr) 2007-10-19
ATE519482T1 (de) 2011-08-15
EA200601450A1 (ru) 2007-04-27
AU2006209371B2 (en) 2012-02-02
JO2746B1 (en) 2014-03-15
SI1762238T1 (sl) 2011-10-28
CA2558764C (fr) 2013-01-08
CY1112223T1 (el) 2015-12-09
EA014381B1 (ru) 2010-10-29
SA110320045B1 (ar) 2014-01-29
RS52003B (en) 2012-04-30
GEP20094741B (en) 2009-07-27
TWI369980B (en) 2012-08-11
NO338079B1 (no) 2016-07-25
AP3045A (en) 2014-11-30
ZA200607532B (en) 2008-05-28
AU2006209371A1 (en) 2007-03-29
DK1762238T3 (da) 2011-11-07
EP1762238A1 (fr) 2007-03-14
PL1762238T3 (pl) 2011-12-30
MXPA06010234A (es) 2007-03-08
US20070066689A1 (en) 2007-03-22
WO2007028903A1 (fr) 2007-03-15
GT200600410A (es) 2007-05-21
HRP20110749T1 (hr) 2011-11-30
MY162318A (en) 2017-05-31
KR20090056949A (ko) 2009-06-03
JP2007077149A (ja) 2007-03-29
AR055418A1 (es) 2007-08-22
ME01964B (me) 2012-04-30
CN1927194A (zh) 2007-03-14
NZ549727A (en) 2008-03-28
FR2890563A1 (fr) 2007-03-16
NO20064049L (no) 2007-03-12
CA2558764A1 (fr) 2007-03-09
KR20070029607A (ko) 2007-03-14
TW200800860A (en) 2008-01-01
AP2008004380A0 (en) 2008-04-30
ES2371482T3 (es) 2012-01-03
UY29776A1 (es) 2006-11-30
EP2301527A1 (fr) 2011-03-30
EP1762238B1 (fr) 2011-08-10
PT1762238E (pt) 2011-09-01
BRPI0603767A (pt) 2007-08-14
UA83541C2 (uk) 2008-07-25

Similar Documents

Publication Publication Date Title
IL196462A (en) (s) - n - (3 - chloro - 4 - cyanophenyl) - 3 - (4 - cyanophenoxy) - 2 - hydroxy - 2 - methylpropanamide, composition and use
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL197924A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL181964A0 (en) Medicaments comprising carbonyl compounds, and the use thereof
EP1731524A4 (en) PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
IL188732A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
IL187534A0 (en) Thiazole derivatives, use thereof and pharmaceutical compositions containing them
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
IL209789A0 (en) Metabolites of 3-(2-dimethylaminomethyl-cyclohexyl)- phenol, pharmaceutical compositions comprising the same and uses thereof
ZA200800439B (en) N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof
EP1731609A4 (en) INHIBITOR OF THE EXPRESSION OF RAD51, MEDICAMENT CONTAINING THE INHIBITOR AS ACTIVE INGREDIENT AND USE THEREOF
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
IL190464A0 (en) Cyclic n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
TW200738635A (en) New salt
EP1902710A4 (en) PHARMACEUTICAL COMPOSITION AND BEVERAGE COMPOSITION COMPRISING L-ARGININE
SG131030A1 (en) New association between agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing it
EP2233467A4 (en) ALPHA-AMINO N-SUBSTITUTED AMIDES, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USES THEREOF
JO2666B1 (en) Use of agomelatine for medications to treat bilateral mental disorders
MY145139A (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
SG131029A1 (en) New association between agomelatine and a thymoregulatory agent and pharmaceutical compositions containing it
EP1945198A4 (en) STABLE PHARMACEUTICAL FORMULATIONS CONTAINING ESCITALOPRAM AND BUPROPION